A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs LY 3127804 (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 28 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Aug 2018.
- 28 Mar 2018 Status changed to active, no longer recruiting.
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.